Evan Bakst Biography and Net Worth

Director of Alphatec

Evan Bakst has served as a Director since March 2018. Mr. Bakst is the Founder and Portfolio Manager of Treetop Capital since 2013, a fundamental, value-oriented investment firm focused primarily on small to midcap healthcare companies. Before launching Treetop, Mr. Bakst spent seven years (2005-2012) at Tremblant Capital, a long/short equity hedge fund, most recently as a Partner where he led the healthcare group. Prior to joining Tremblant, Mr. Bakst was a Principal at JPMorgan Partners, LLC (2000-2005), where he shared the day-to-day responsibility for managing the healthcare buyout practice. Previously, Mr. Bakst was a Managing Director at The Beacon Group, a private equity/M&A boutique and, prior to that, Mr. Bakst worked as a Consultant at Bain and Company, providing strategic and operational advice to a major healthcare company. Mr. Bakst is currently on the Board of Sonacare Medical, LLC, and was formerly on the Boards of Accordant Health Services, Cadent Holdings, Inc., FundsXpress Inc., Iasis Healthcare, MedQuest Associates, National Surgical Care, Quality Tubing Inc. and ValueOptions. Mr. Bakst earned a B.A. in Economics from the University of California, Berkeley, and an M.B.A. from the Harvard Business School.

What is Evan Bakst's net worth?: The estimated net worth of Evan Bakst is at least $136,200.00 as of March 14th, 2024. Mr. Bakst owns 15,000 shares of Alphatec stock worth more than $136,200 as of December 31st. This net worth evaluation does not reflect any other investments that Mr. Bakst may own. Learn More about Evan Bakst's net worth.
How do I contact Evan Bakst?: The corporate mailing address for Mr. Bakst and other Alphatec executives is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. Alphatec can also be reached via phone at (760) 431-9286 and via email at [email protected]. Learn More on Evan Bakst's contact information.
Has Evan Bakst been buying or selling shares of Alphatec?: Evan Bakst has not been actively trading shares of Alphatec during the last quarter. Most recently, on Thursday, March 14th, Evan Bakst bought 15,000 shares of Alphatec stock. The stock was acquired at an average cost of $13.53 per share, with a total value of $202,950.00. Following the completion of the transaction, the director now directly owns 15,000 shares of the company's stock, valued at $202,950. Learn More on Evan Bakst's trading history.
Who are Alphatec's active insiders?: Alphatec's insider roster includes Evan Bakst (Director), Jeffrey Black (CFO), Jason Hochberg (Director), Craig Hunsaker (EVP), Scott Lish (SVP), Patrick Miles (CEO), David Mowry (Director), David Pelizzon (Director), Jennifer Pritzker (Major Shareholder), Paul Segal (Major Shareholder), David Sponsel (EVP), and James Tullis (Director). Learn More on Alphatec's active insiders.
Are insiders buying or selling shares of Alphatec?: In the last twelve months, Alphatec insiders bought shares 3 times. They purchased a total of 85,000 shares worth more than $743,050.00. In the last twelve months, insiders at the medical technology company sold shares 11 times. They sold a total of 337,801 shares worth more than $4,555,519.43. The most recent insider tranaction occured on August, 21st when Director David M Demski bought 50,000 shares worth more than $283,500.00. Insiders at Alphatec own 22.8% of the company. Learn More about insider trades at Alphatec.
Information on this page was last updated on 8/21/2024.

Evan Bakst Insider Trading History at Alphatec

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2024	Buy	15,000	$13.53	$202,950.00	15,000
8/23/2023	Sell	8,700	$14.92	$129,804.00	1,089,038
11/26/2021	Buy	10,000	$10.57	$105,700.00
3/11/2019	Buy	20,566	$2.59	$53,265.94	726,912

Evan Bakst Buying and Selling Activity at Alphatec

Alphatec Company Overview

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Today's Range

Now: $9.08

$8.95

$9.24

50 Day Range

MA: $8.81

$5.13

$10.48

2 Week Range

Now: $9.08

$4.88

$17.34

Volume

783,055 shs

Average Volume

1,897,185 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

$20k in extra income?

From DTI | Ad

My friend Alex Reid just might have created my favorite strategy right now. You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible…. While still showing his traders how to target big money. This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared. And that’s just just a quarter of the total trade alerts he’s sent out. The true total profit potential his beta-testers have had the chance to target is far larger than $20k.

Alex recorded a special video training where he reveals exactly how much.